CD19 CAR-T for lymphoma: real-world experience in the UK

(6:1econd)

Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cells

(6:13)

CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell ALL

(2:36)

CD19 CAR T-cells for adults

(4:47)

CD19 CAR T-cell therapy for lymphoma

(2:55)

CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s Experience

(57:3)

Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells

(45)

Dr. Shah on Differences Between Anti–CD19 CAR T-Cell Therapies

(1:29)

UKM-OnlineTalk | Krebs mit CAR-T-Zellen bekämpfen

(45:21)

Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignancies

(2:37)

CD19 and CD20 CAR T-cell therapy for non-Hodgkin lymphoma

(2:22)

CD19 Targeted CAR T-cell Therapy in LBCL

(45:46)

Clinical data for CD19-directed CAR T-cell products in ALL

(2:26)

B cell lymphoma model for CD19 CAR T Cells evaluation | Protocol Preview

(2:1econd)

CD19 CAR-T Cell Treatment: Unravelling the Role of B Cells in SLE

(5:12)

Therapeutic T cell engineering: CD19 CAR therapy and beyond

(40:38)

CD19 CAR-T for CNS lymphoma

(1:39)

CD19 CAR T Cell Therapy in SLE (9.16.2022)

(18:59)

Evaluating post-infusion CAR-Treg cells to identify patients resistant to CD19 CAR-T therapy

(1:29)

Repeat infusions of CD19 CAR-T

(3:6)